Jefferies Maintains Buy on Amarin Corp. (AMRN)

Jefferies is out with its report today on Amarin Corp.

, maintaining Buy. In a note to clients, Jefferies writes, "We believe AMR101 offers robust efficacy for hyperlipidemia, lowering triglycerides without raising cholesterol like Lovaza. With a cleaner profile and potentially a broader label, we believe AMR101 could realize a multibillion-dollar opportunity. We reach our 12-month price target price of $12/share based on a sum-of-the-parts DCF analysis (AMR101 $11 + cash $1)." Shares of AMRN closed yesterday at $8.42, down 2.09% from Tuesday's close.